Pieris Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Pieris Pharmaceuticals has been growing earnings at an average annual rate of 1%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 3% per year.
Key information
1.0%
Earnings growth rate
11.0%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | -3.0% |
Return on equity | -74.0% |
Net Margin | -39.7% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pieris Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 41 | -16 | 17 | 0 |
31 Dec 23 | 43 | -25 | 17 | 0 |
30 Sep 23 | 47 | -28 | 19 | 0 |
30 Jun 23 | 33 | -27 | 16 | 0 |
31 Mar 23 | 17 | -41 | 16 | 0 |
31 Dec 22 | 26 | -33 | 16 | 0 |
30 Sep 22 | 28 | -35 | 16 | 0 |
30 Jun 22 | 27 | -42 | 17 | 0 |
31 Mar 22 | 27 | -47 | 17 | 0 |
31 Dec 21 | 31 | -46 | 17 | 0 |
30 Sep 21 | 25 | -51 | 16 | 0 |
30 Jun 21 | 24 | -48 | 16 | 0 |
31 Mar 21 | 32 | -38 | 16 | 0 |
31 Dec 20 | 29 | -37 | 17 | 0 |
30 Sep 20 | 45 | -26 | 18 | 0 |
30 Jun 20 | 57 | -15 | 18 | 0 |
31 Mar 20 | 51 | -22 | 18 | 0 |
31 Dec 19 | 46 | -28 | 18 | 0 |
30 Sep 19 | 34 | -36 | 19 | 13 |
30 Jun 19 | 27 | -40 | 18 | 24 |
31 Mar 19 | 33 | -28 | 19 | 34 |
31 Dec 18 | 29 | -27 | 18 | 41 |
30 Sep 18 | 42 | -8 | 21 | 33 |
30 Jun 18 | 38 | -8 | 19 | 28 |
31 Mar 18 | 28 | -18 | 18 | 24 |
31 Dec 17 | 25 | -18 | 18 | 22 |
30 Sep 17 | 10 | -32 | 14 | 23 |
30 Jun 17 | 7 | -31 | 13 | 22 |
31 Mar 17 | 6 | -27 | 11 | 21 |
31 Dec 16 | 6 | -23 | 9 | 19 |
30 Sep 16 | 5 | -19 | 9 | 15 |
30 Jun 16 | 5 | -17 | 9 | 13 |
31 Mar 16 | 4 | -15 | 8 | 10 |
31 Dec 15 | 3 | -14 | 9 | 8 |
30 Sep 15 | 4 | -15 | 10 | 7 |
30 Jun 15 | 4 | -13 | 8 | 6 |
31 Mar 15 | 4 | -13 | 9 | 6 |
31 Dec 14 | 5 | -10 | 7 | 5 |
30 Sep 14 | 6 | -5 | 5 | 5 |
31 Dec 13 | 12 | 0 | 3 | 9 |
Quality Earnings: PI60 is currently unprofitable.
Growing Profit Margin: PI60 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PI60 is unprofitable, but has reduced losses over the past 5 years at a rate of 1% per year.
Accelerating Growth: Unable to compare PI60's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PI60 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: PI60 has a negative Return on Equity (-73.99%), as it is currently unprofitable.